Arrowhead Pharmaceuticals, Inc. Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Million

Consolidate Quarterly Results

Dec'25

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Jun'24

Net Sales

264.03

256.47

27.77

542.71

2.50

0.00

Other Operating Income

0.00

Total Operating income

264.03

256.47

27.77

542.71

2.50

0.00

Raw Material Cost

6.39

6.22

6.08

5.24

5.03

4.78

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

61.35

56.35

47.54

50.79

49.68

51.35

48.32

Power Cost

0.00

Manufacturing Expenses

22.50

21.69

24.38

21.64

21.65

14.65

5.09

Selling and Distribution Expenses

45.52

37.18

30.44

27.89

26.40

25.79

23.20

Other Expenses

8.75

9.08

8.47

5.51

6.09

6.54

9.47

Total Expenditure (Excl Depreciation)

223.22

212.37

193.32

161.51

163.91

162.20

176.14

Operating Profit (PBDIT) excl Other Income

40.8

44.1

-165.5

381.2

-161.4

-162.2

-176.1

Other Income

9.97

13.71

10.84

10.05

7.94

4.05

7.26

Operating Profit (PBDIT)

57.17

64.20

-148.48

397.34

-148.23

-153.13

-164.10

Interest

22.50

21.69

24.38

21.64

21.65

14.65

5.09

Exceptional Items

0.00

Gross Profit (PBDT)

257.64

250.09

21.54

536.62

-2.73

-5.03

-4.78

Depreciation

6.39

6.22

6.08

5.24

5.03

4.78

Profit Before Tax

28.27

36.12

-179.09

369.62

-175.12

-172.80

-173.98

Tax

0.03

20.00

-0.44

1.75

0.10

0.55

0.00

Provisions and contingencies

0.00

Profit After Tax

30.81

-23.75

-175.24

370.44

-173.09

-170.54

-170.79

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

30.81

-23.75

-175.24

370.44

-173.09

-170.54

-170.79

Share in Profit of Associates

0.00

Minority Interest

-2.57

39.87

-3.41

-2.58

-2.13

-2.81

-3.18

Other related items

0.00

Consolidated Net Profit

28.24

16.12

-178.65

367.86

-175.22

-173.34

-173.98

Equity Capital

0.00

Face Value

0.0

Reserves

568.42

466.05

522.31

683.32

52.59

185.44

330.55

Earnings per share (EPS)

0.22

-0.17

-1.26

2.75

-1.39

-1.37

-1.38

Diluted Earnings per share

0.22

-0.17

-1.26

2.75

-1.39

-1.37

-1.38

Operating Profit Margin (Excl OI)

15.46%

17.2%

-596.21%

70.24%

-6456.48%

0.0%

Gross Profit Margin

13.13%

16.57%

-622.56%

69.23%

-6795.2%

0.0%

PAT Margin

11.67%

-9.26%

-631.11%

68.26%

-6923.4%

0.0%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - QoQ

Net Sales

QoQ Growth in quarter ended Dec 2025 is 2.92% vs 822.66% in Sep 2025

Consolidate Net Profit

QoQ Growth in quarter ended Dec 2025 is 75.16% vs 109.01% in Sep 2025

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Dec 2025 is -6.53% vs 131.70% in Sep 2025

Interest

QoQ Growth in quarter ended Dec 2025 is 3.69% vs -11.07% in Sep 2025

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Dec 2025 has fallen from Sep 2025

Compare Quarterly Results Of Arrowhead Pharmaceuticals, Inc. With

Select Peers

Figures in Million

Consolidate Quarterly Results

Change(USD)

Change(%)

Net Sales

264.03

16.40

247.63

1,509.94%

Other Operating Income

0.00

Total Operating income

264.03

16.40

247.63

1,509.94%

Raw Material Cost

6.39

2.54

3.85

151.57%

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

61.35

0.00

61.35

Power Cost

0.00

Manufacturing Expenses

22.50

0.00

22.50

Selling and Distribution Expenses

45.52

72.00

-26.48

-36.78%

Other Expenses

8.75

11.39

-2.64

-23.18%

Total Expenditure (Excl Depreciation)

223.22

188.45

34.77

18.45%

Operating Profit (PBDIT) excl Other Income

40.81

-172.05

212.86

123.72%

Other Income

9.97

11.15

-1.18

-10.58%

Operating Profit (PBDIT)

57.17

-159.79

216.96

135.78%

Interest

22.50

0.00

22.50

Exceptional Items

0.00

-1.00

1.00

100.00%

Gross Profit (PBDT)

257.64

13.86

243.78

1,758.87%

Depreciation

6.39

1.11

5.28

475.68%

Profit Before Tax

28.27

-161.90

190.17

117.46%

Tax

0.03

0.00

0.03

Provisions and contingencies

0.00

Profit After Tax

30.81

-161.90

192.71

119.03%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

30.81

-161.90

192.71

119.03%

Share in Profit of Associates

0.00

Minority Interest

-2.57

0.00

-2.57

Other related items

0.00

Consolidated Net Profit

28.24

-161.90

190.14

117.44%

Equity Capital

0.00

Face Value

0.00

Reserves

568.42

946.47

-378.05

-39.94%

Earnings per share (EPS)

0.22

-2.49

2.71

108.84%

Diluted Earnings per share

0.22

-2.49

2.71

108.84%

Operating Profit Margin (Excl OI)

15.46%

-1,049.11%

0.00

1,064.57%

Gross Profit Margin

13.13%

-980.42%

0.00

993.55%

PAT Margin

11.67%

-987.22%

0.00

998.89%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Quarterly - Net Sales

Net Sales 26.40 Million

in Dec 2025

Figures in Million

QoQ Growth in quarter ended Dec 2025 is 2.92% vs 822.66% in Sep 2025

YoY Growth in quarter ended Dec 2025 is 10,460.00% vs -30.56% in Dec 2024

Quarterly - Consolidate Net Profit

Consolidate Net Profit 2.82 Million

in Dec 2025

Figures in Million

QoQ Growth in quarter ended Dec 2025 is 75.16% vs 109.01% in Sep 2025

YoY Growth in quarter ended Dec 2025 is 116.10% vs -29.39% in Dec 2024

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 4.72 Million

in Dec 2025

Figures in Million

QoQ Growth in quarter ended Dec 2025 is -6.53% vs 131.70% in Sep 2025

YoY Growth in quarter ended Dec 2025 is 130.22% vs -18.07% in Dec 2024

Quarterly - Interest

Interest 2.25 Million

in Dec 2025

Figures in Million

QoQ Growth in quarter ended Dec 2025 is 3.69% vs -11.07% in Sep 2025

YoY Growth in quarter ended Dec 2025 is 4.17% vs 300.00% in Dec 2024

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 15.46%

in Dec 2025

Figures in %

QoQ Growth in quarter ended Dec 2025 has fallen from Sep 2025

YoY Growth in quarter ended Dec 2025 has improved from Dec 2024